Execs On The Move, September 2014
Executive Summary
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: safety debate as more lecanemab data reported; amyloid discussions continue at Alzheimer’s meeting; China COVID unrest affect country’s biotech sector; and Merck’s CMO talks about post-Keytruda plans.
To Prevent Shortages, US FDA Wants Sponsor To Provide Notifications Of Demand Spike
Demand-related shortages are a relatively new problem, but the FDA maintains their tools can prevent or end them.
Eisai Plots A Meticulous Path To CMS Coverage For Lecanemab
The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab.